Standard

Antimetastatic Activity of Combined Topotecan and Tyrosyl-DNA Phosphodiesterase-1 Inhibitor on Modeled Lewis Lung Carcinoma. / Koldysheva, E. V.; Men’shchikova, A. P.; Lushnikova, E. L. et al.

In: Bulletin of Experimental Biology and Medicine, Vol. 166, No. 5, 15.03.2019, p. 661-666.

Research output: Contribution to journal › Article › peer-review

Harvard

Koldysheva, EV, Men’shchikova, AP, Lushnikova, EL, Popova, NA, Kaledin, VI, Nikolin, VP, Zakharenko, AL, Luzina, OA, Salakhutdinov, NF & Lavrik, OI 2019, 'Antimetastatic Activity of Combined Topotecan and Tyrosyl-DNA Phosphodiesterase-1 Inhibitor on Modeled Lewis Lung Carcinoma', Bulletin of Experimental Biology and Medicine, vol. 166, no. 5, pp. 661-666. https://doi.org/10.1007/s10517-019-04413-3

APA

Koldysheva, E. V., Men’shchikova, A. P., Lushnikova, E. L., Popova, N. A., Kaledin, V. I., Nikolin, V. P., Zakharenko, A. L., Luzina, O. A., Salakhutdinov, N. F., & Lavrik, O. I. (2019). Antimetastatic Activity of Combined Topotecan and Tyrosyl-DNA Phosphodiesterase-1 Inhibitor on Modeled Lewis Lung Carcinoma. Bulletin of Experimental Biology and Medicine, 166(5), 661-666. https://doi.org/10.1007/s10517-019-04413-3

Vancouver

Koldysheva EV, Men’shchikova AP, Lushnikova EL, Popova NA, Kaledin VI, Nikolin VP et al. Antimetastatic Activity of Combined Topotecan and Tyrosyl-DNA Phosphodiesterase-1 Inhibitor on Modeled Lewis Lung Carcinoma. Bulletin of Experimental Biology and Medicine. 2019 Mar 15;166(5):661-666. doi: 10.1007/s10517-019-04413-3

Author

Koldysheva, E. V. ; Men’shchikova, A. P. ; Lushnikova, E. L. et al. / Antimetastatic Activity of Combined Topotecan and Tyrosyl-DNA Phosphodiesterase-1 Inhibitor on Modeled Lewis Lung Carcinoma. In: Bulletin of Experimental Biology and Medicine. 2019 ; Vol. 166, No. 5. pp. 661-666.

BibTeX

@article{9bbc41f766d24b41abb85b13273f1da3,
title = "Antimetastatic Activity of Combined Topotecan and Tyrosyl-DNA Phosphodiesterase-1 Inhibitor on Modeled Lewis Lung Carcinoma",
abstract = "The antimetastatic activity of combined or individual administration of topotecan and tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibitor was examined under various administration schedules in mice with Lewis lung carcinoma modeled by intravenous injection of 200,000 clone/mouse. The greatest antimetastatic effect was observed after combined use of topotecan and Tdp1 inhibitor as documented by macroscopic study of the lungs that revealed the decreased metastatic scores by 76, 91, or 74% at the respective inhibitor doses of 2, 4, or 6 mg/mouse, respectively, in parallel with inhibition of metastasis up to 98% (at inhibitor dose of 4 mg/mouse) and morphological and morphometric analyses of the lung sections, which revealed elevation of metastasis growth delay index to 86 and 63% at the respective inhibitor doses of 4 and 6 mg/mouse, respectively. The combined administration of topotecan and Tdp1 inhibitor is viewed as the most effective way to eliminate the metastatic formations with possible restitution of focal lesions.",
keywords = "Lewis lung carcinoma, metastases, morphometry, topotecan, tyrosyl-DNA phosphodiesterase-1 inhibitor",
author = "Koldysheva, {E. V.} and Men{\textquoteright}shchikova, {A. P.} and Lushnikova, {E. L.} and Popova, {N. A.} and Kaledin, {V. I.} and Nikolin, {V. P.} and Zakharenko, {A. L.} and Luzina, {O. A.} and Salakhutdinov, {N. F.} and Lavrik, {O. I.}",
year = "2019",
month = mar,
day = "15",
doi = "10.1007/s10517-019-04413-3",
language = "English",
volume = "166",
pages = "661--666",
journal = "Bulletin of Experimental Biology and Medicine",
issn = "0007-4888",
publisher = "Springer New York",
number = "5",

}

RIS

TY - JOUR

T1 - Antimetastatic Activity of Combined Topotecan and Tyrosyl-DNA Phosphodiesterase-1 Inhibitor on Modeled Lewis Lung Carcinoma

AU - Koldysheva, E. V.

AU - Men’shchikova, A. P.

AU - Lushnikova, E. L.

AU - Popova, N. A.

AU - Kaledin, V. I.

AU - Nikolin, V. P.

AU - Zakharenko, A. L.

AU - Luzina, O. A.

AU - Salakhutdinov, N. F.

AU - Lavrik, O. I.

PY - 2019/3/15

Y1 - 2019/3/15

N2 - The antimetastatic activity of combined or individual administration of topotecan and tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibitor was examined under various administration schedules in mice with Lewis lung carcinoma modeled by intravenous injection of 200,000 clone/mouse. The greatest antimetastatic effect was observed after combined use of topotecan and Tdp1 inhibitor as documented by macroscopic study of the lungs that revealed the decreased metastatic scores by 76, 91, or 74% at the respective inhibitor doses of 2, 4, or 6 mg/mouse, respectively, in parallel with inhibition of metastasis up to 98% (at inhibitor dose of 4 mg/mouse) and morphological and morphometric analyses of the lung sections, which revealed elevation of metastasis growth delay index to 86 and 63% at the respective inhibitor doses of 4 and 6 mg/mouse, respectively. The combined administration of topotecan and Tdp1 inhibitor is viewed as the most effective way to eliminate the metastatic formations with possible restitution of focal lesions.

AB - The antimetastatic activity of combined or individual administration of topotecan and tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibitor was examined under various administration schedules in mice with Lewis lung carcinoma modeled by intravenous injection of 200,000 clone/mouse. The greatest antimetastatic effect was observed after combined use of topotecan and Tdp1 inhibitor as documented by macroscopic study of the lungs that revealed the decreased metastatic scores by 76, 91, or 74% at the respective inhibitor doses of 2, 4, or 6 mg/mouse, respectively, in parallel with inhibition of metastasis up to 98% (at inhibitor dose of 4 mg/mouse) and morphological and morphometric analyses of the lung sections, which revealed elevation of metastasis growth delay index to 86 and 63% at the respective inhibitor doses of 4 and 6 mg/mouse, respectively. The combined administration of topotecan and Tdp1 inhibitor is viewed as the most effective way to eliminate the metastatic formations with possible restitution of focal lesions.

KW - Lewis lung carcinoma

KW - metastases

KW - morphometry

KW - topotecan

KW - tyrosyl-DNA phosphodiesterase-1 inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85063660758&partnerID=8YFLogxK

U2 - 10.1007/s10517-019-04413-3

DO - 10.1007/s10517-019-04413-3

M3 - Article

C2 - 30903487

AN - SCOPUS:85063660758

VL - 166

SP - 661

EP - 666

JO - Bulletin of Experimental Biology and Medicine

JF - Bulletin of Experimental Biology and Medicine

SN - 0007-4888

IS - 5

ER -

ID: 19038248